The DOI matches its Crossref record.
DILI and Drug Development: A Regulatory Perspective
Abstract
The assessment of risk for serious, life-threatening drug-induced liver injury (DILI) associated with a suspect drug, biological agent, or herbal product depends on an iterative analysis of pre- and postmarket datastreams. Because serious cases of idiosyncratic DILI are typically rare, regulatory scientists seek strategies that accurately predict from clinical trial data which study drugs will be likely to cause these events in a large postmarket treatment population, e.g., through the identification of cases that are consistent with Hy's law. This objective is only achievable if rigorous standards in study subject monitoring, data collection and analysis of liver injury cases for causality are followed. In the future, the development of more effective predictive and analytic tools in preclinical and clinical testing will provide a framework to reliably identify new agents that have hepatotoxic profiles as well as those individuals who are susceptible to develop serious DILI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The package inserts of currently approved drugs may recommend (i) monitoring, with or without providing a schedule for testing or any instructions; (ii) therapy discontinuation if symptoms and/or signs of liver injury supervene; or (iii) medication discontinuation or interruption for specified laboratory abnormalities.174,175”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [174]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Suzman, D. L., Pelosof, L., Rosenberg, A., & Avigan, M. I. (2018) · Liver International · doi:10.1111/liv.13746 · Cited by 189
Self-citationBenesic, A., Rotter, I., Dragoi, D., Weber, S., Buchholtz, M.-L., & Gerbes, A. L. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.049 · Cited by 52
Amirzadegan, J., Vouffo, E. C., Lan, L., Navarro Almario, E., Avigan, M. I., & Hayashi, P. H. (2026) · Drug Safety · doi:10.1007/s40264-025-01603-z · Cited by 3
Self-citation
Metadata
- Authors
- Avigan, M.
- Affiliations
- Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2014-05-31
- Volume
- 34
- Issue
- 02
- Pages
- 215-226
- ISSN
- 0272-8087
- 1098-8971
- Cited by
- 30
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DILI and Drug Development: A Regulatory Perspective. https://app.cochat.ai/papers/10.1055/s-0034-1375961
- The paper
- Avigan, M. (2014). DILI and Drug Development: A Regulatory Perspective. Seminars in Liver Disease. https://doi.org/10.1055/s-0034-1375961
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.